“The approval of safe and effective companion diagnostic tests and drugs continue to be important developments in oncology”, said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health.
Advertisement
Pasi A Jänne MD, PhD, Director, Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, Scientific Director, Belfer Centre for Applied Cancer Science and Professor of Medicine, Harvard Medical School, said: “In the AURA clinical studies, AZD9291 has demonstrated compelling early efficacy and tolerability in patients with EGFRm T790M metastatic non-small cell lung cancer”. Tagrisso isn’t the only lung cancer treatment that AstraZeneca is now producing but, as it targets advanced cases of the disease caused by the specific T790M mutation, it will help widen the company’s treatment options for all the different stages of the disease. He said the drug would be available at a copay of as little as $25-per-month. “We’ve labored very exhausting at early conversations with payers and plans, and we’ve had very constructive conversations up to now”, he stated. “We’re expecting to be able to get the right level of access to patients”.
Tagrisso is marketed by Astra Zeneca Pharmaceuticals based in Wilmington, Delaware. The drug entered its first human trial in 2013, and has sped through development thanks to a series of priority designations by the FDA. These research confirmed the drug shrunk tumors in fifty nine% of circumstances.
AstraZeneca on Friday announced that the Food and Drug Administration had approved the company’s Tagrisso (osimertinib) tablets. This type of cancer accounts for roughly a third of all cancer deaths and has a survival rate of only 20 percent over a period of 5 years.
Tagrisso has been a key plank within the firm’s ambition to extend its income to $forty five billion by 2023, in contrast with round $26 billion in 2014.
The treatment, developed in Cheshire, is one of several highlighted by AstraZeneca chief executive Pascal Soriot in his defence against a £69bn takeover approach from American rival Pfizer, the maker of Viagra, last year.
Industry analysts are more cautious about sales in the next few years, with consensus expectations pointing to revenue of $1.1 billion in 2020, according to Thomson Reuters Cortellis.
Advertisement
Write to Denise. Roland at Denise.
